Skip to main content
Erschienen in: Archives of Virology 1/2019

05.10.2018 | Original Article

Development and comparison of two H5N8 influenza A vaccine candidate strains

verfasst von: Mi-Seon Lee, Eun Young Jang, Junhyung Cho, Kisoon Kim, Chan Hee Lee, Hwajung Yi

Erschienen in: Archives of Virology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Avian influenza viruses circulating in birds have caused outbreaks of infection in poultry and humans, thereby threatening public health. Recently, a highly pathogenic avian influenza (HPAI) virus (H5N8) of clade 2.3.4.4 emerged in Korea and other countries and caused multiple outbreaks in domestic and wild birds, with concerns for human infection. To combat HPAI viral infections, novel vaccines are likely to be the most effective approach. Therefore, in this study, we generated H5N8 vaccine candidate viruses based on a Korean isolate (A/broiler duck/Korea/Buan2/2014). The vaccine candidate viruses were 2:6 reassortants expressing the two surface glycoproteins of A/broiler duck/Korea/Buan2/2014 on an A/Puerto Rico/8/34 (PR8) backbone generated by using an eight-plasmid-based reverse genetics system with or without replacement of the multi-basic amino acid cleavage motif (MBCM, a crucial pathogenic factor in HPAI virus) with a bi-basic amino acid cleavage motif (BBCM) in their HA. An H5N8 vaccine candidate virus containing the BBCM showed attenuated pathogenesis in embryonated eggs and exhibited less virulence in the infected mice compared with the wild H5N8 virus containing an MBCM. Vaccination with an inactivated preparation of the vaccine candidate virus protected mice from lethal H5N8 viral challenge. This is the first report of the development and evaluation of H5N8 vaccine strains (with an MBCM or BBCM) of HA clade 2.3.4.4 as vaccine candidates. Our findings suggest that H5N8 strains with a BBCM instead of an MBCM might be considered for H5N8 vaccine seed virus development or as a reference vaccine against H5N8 viral strains.
Literatur
4.
8.
Zurück zum Zitat Jhung MA, Nelson DI, Control CfD, Prevention (2015) Outbreaks of avian influenza A (H5N2),(H5N8), and (H5N1) among birds—United States, December 2014–January 2015. MMWR Morb Mortal Wkly Rep 64(4):111PubMedPubMedCentral Jhung MA, Nelson DI, Control CfD, Prevention (2015) Outbreaks of avian influenza A (H5N2),(H5N8), and (H5N1) among birds—United States, December 2014–January 2015. MMWR Morb Mortal Wkly Rep 64(4):111PubMedPubMedCentral
11.
Zurück zum Zitat Si Y-J, Choi WS, Kim Y-I, Lee I-W, Kwon H-I, Park S-J, Kim E-H, Sm Kim, Kwon J-J, Song M-S, Kim C-J, Choi Y-K (2016) Genetic characteristics of highly pathogenic H5N8 avian influenza viruses isolated from migratory wild birds in South Korea during 2014-2015. Arch Virol 161(10):2749–2764. https://doi.org/10.1007/s00705-016-2979-4 CrossRefPubMed Si Y-J, Choi WS, Kim Y-I, Lee I-W, Kwon H-I, Park S-J, Kim E-H, Sm Kim, Kwon J-J, Song M-S, Kim C-J, Choi Y-K (2016) Genetic characteristics of highly pathogenic H5N8 avian influenza viruses isolated from migratory wild birds in South Korea during 2014-2015. Arch Virol 161(10):2749–2764. https://​doi.​org/​10.​1007/​s00705-016-2979-4 CrossRefPubMed
17.
18.
Zurück zum Zitat Ostrowsky B, Huang A, Terry W, Anton D, Brunagel B, Traynor L, Abid S, Johnson G, Kacica M, Katz J, Edwards L, Lindstrom S, Klimov A (2003) Uyeki TM (2012) Uyeki TM (2012) Low pathogenic avian influenza A (H7N2) virus infection in immunocompromised adult, New York, USA. Emerg Infect Dis 18(7):1128–1131. https://doi.org/10.3201/eid1807.111913 CrossRef Ostrowsky B, Huang A, Terry W, Anton D, Brunagel B, Traynor L, Abid S, Johnson G, Kacica M, Katz J, Edwards L, Lindstrom S, Klimov A (2003) Uyeki TM (2012) Uyeki TM (2012) Low pathogenic avian influenza A (H7N2) virus infection in immunocompromised adult, New York, USA. Emerg Infect Dis 18(7):1128–1131. https://​doi.​org/​10.​3201/​eid1807.​111913 CrossRef
25.
Zurück zum Zitat Senne D, Panigrahy B, Kawaoka Y, Pearson J, Süss J, Lipkind M, Kida H, Webster R (1996) Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. Avian Dis 40(2):425–437. https://doi.org/10.2307/1592241 CrossRefPubMed Senne D, Panigrahy B, Kawaoka Y, Pearson J, Süss J, Lipkind M, Kida H, Webster R (1996) Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. Avian Dis 40(2):425–437. https://​doi.​org/​10.​2307/​1592241 CrossRefPubMed
32.
Zurück zum Zitat Palmer DF, Dowdle WR, Coleman MT, Schild GC (1975) Hemagglutination-inhibition test. In: Advanced laboratory techniques for influenza diagnosis: procedural guide. U.S. Department of Health, Education and Welfare, Atlanta, GA, pp 25–62 Palmer DF, Dowdle WR, Coleman MT, Schild GC (1975) Hemagglutination-inhibition test. In: Advanced laboratory techniques for influenza diagnosis: procedural guide. U.S. Department of Health, Education and Welfare, Atlanta, GA, pp 25–62
37.
Zurück zum Zitat Pan M, Gao R, Lv Q, Huang S, Zhou Z, Yang L, Li X, Zhao X, Zou X, Tong W, Mao S, Zou S, Bo H, Zhu X, Liu L, Yuan H, Zhang M, Wang D, Li Z, Zhao W, Ma M, Li Y, Li T, Yang H, Xu J, Zhou L, Zhou X, Tang W, Song Y, Chen T, Bai T, Zhou J, Wang D, Wu G, Li D, Feng Z, Gao GF, Wang Y, He S, Shu Y (2016) Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: virological and clinical findings. J Infect 72(1):52–59. https://doi.org/10.1016/j.jinf.2015.06.009 CrossRefPubMed Pan M, Gao R, Lv Q, Huang S, Zhou Z, Yang L, Li X, Zhao X, Zou X, Tong W, Mao S, Zou S, Bo H, Zhu X, Liu L, Yuan H, Zhang M, Wang D, Li Z, Zhao W, Ma M, Li Y, Li T, Yang H, Xu J, Zhou L, Zhou X, Tang W, Song Y, Chen T, Bai T, Zhou J, Wang D, Wu G, Li D, Feng Z, Gao GF, Wang Y, He S, Shu Y (2016) Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: virological and clinical findings. J Infect 72(1):52–59. https://​doi.​org/​10.​1016/​j.​jinf.​2015.​06.​009 CrossRefPubMed
43.
Zurück zum Zitat Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Liu Y, Wang X, Wood J, Feng Z, Wang Y, Yin W (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368(9540):991–997. https://doi.org/10.1016/S0140-6736(06)69294-5 CrossRefPubMed Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Liu Y, Wang X, Wood J, Feng Z, Wang Y, Yin W (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368(9540):991–997. https://​doi.​org/​10.​1016/​S0140-6736(06)69294-5 CrossRefPubMed
46.
Zurück zum Zitat Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nøstbakken JK, Weverling GJ, Klap J, McCullough KC, Zambon M, Kompier R, Sjursen H (2011) Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 29(45):8049–8059. https://doi.org/10.1016/j.vaccine.2011.08.042 CrossRefPubMed Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nøstbakken JK, Weverling GJ, Klap J, McCullough KC, Zambon M, Kompier R, Sjursen H (2011) Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 29(45):8049–8059. https://​doi.​org/​10.​1016/​j.​vaccine.​2011.​08.​042 CrossRefPubMed
Metadaten
Titel
Development and comparison of two H5N8 influenza A vaccine candidate strains
verfasst von
Mi-Seon Lee
Eun Young Jang
Junhyung Cho
Kisoon Kim
Chan Hee Lee
Hwajung Yi
Publikationsdatum
05.10.2018
Verlag
Springer Vienna
Erschienen in
Archives of Virology / Ausgabe 1/2019
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-018-4062-9

Weitere Artikel der Ausgabe 1/2019

Archives of Virology 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.